pyrazines has been researched along with Lymphoma, T-Cell, Cutaneous in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biskup, E; Gniadecki, R; Kamstrup, MR; Manfé, V | 1 |
| Chang, TP; Poltoratsky, V; Vancurova, I | 1 |
| Biskup, E; Gniadecki, R; Naym, DG | 1 |
| Ding, J; Iida, S; Inagaki, A; Ishida, T; Ito, A; Komatsu, H; Kusumoto, S; Ri, M; Ueda, R; Utsunomiya, A; Yano, H | 1 |
| Assaf, C; Heider, U; Lamottke, B; Mieth, M; Moebs, M; Rademacher, J; Sezer, O; von Metzler, I | 1 |
| Celiker, MY; Chang, TP; Ghosh, CC; Juvekar, A; Manna, S; Ramaswami, S; Vancurova, I; Vu, HY | 1 |
| Araujo, ME; Bates, SE; Bishton, M; Dai, Y; Grant, S; Harrison, SJ; Johnstone, RW; Lee, B; Piekarz, RL; Prince, HM | 1 |
| Bachelez, H; Courtois, G; Dubertret, L; Jean-Louis, F; Laroche, L; Michel, L; Pellet, C; Sors, A | 1 |
| Baron, P; Polsky, B; Prochaska, HJ; Yeh, Y | 1 |
9 other study(ies) available for pyrazines and Lymphoma, T-Cell, Cutaneous
| Article | Year |
|---|---|
Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
Topics: Amyloid Precursor Protein Secretases; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Enzyme Inhibitors; Humans; Leupeptins; Lymphoma, T-Cell, Cutaneous; NF-kappa B; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptor, Notch1; Skin Neoplasms; Tumor Suppressor Protein p53 | 2013 |
Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Proteins; Interleukin-10; Interleukin-17; Interleukin-8; Lymphoma, T-Cell, Cutaneous; Models, Genetic; NF-kappa B; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Protein Binding; Pyrazines; Receptors, CXCR4; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Skin Neoplasms; Transforming Growth Factor beta1 | 2015 |
Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation.
Topics: Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Flow Cytometry; Histones; Humans; Isoxazoles; Lymphoma, T-Cell, Cutaneous; Phosphorylation; Photochemotherapy; Photosensitizing Agents; Pyrazines; Quinolines; Quinuclidines; RNA, Small Interfering; Sulfones; Tumor Cells, Cultured; Ultraviolet Rays | 2016 |
Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.
Topics: Adult; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Humans; Immunoprecipitation; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-Cell, Cutaneous; Membrane Potential, Mitochondrial; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation | 2009 |
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, T-Cell, Cutaneous; Pharmacokinetics; Pyrazines; Reactive Oxygen Species; Vorinostat | 2009 |
Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.
Topics: Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus; DNA, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; I-kappa B Proteins; Leupeptins; Lymphoma, T-Cell, Cutaneous; Molecular Sequence Data; NF-kappa B; NF-kappa B p50 Subunit; NF-KappaB Inhibitor alpha; Protein Binding; Protein Subunits; Protein Transport; Pyrazines; Transcription Factor RelA; Transcription, Genetic | 2011 |
A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Depsipeptides; Drug Evaluation, Preclinical; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lymphoma, T-Cell, Cutaneous; Neovascularization, Pathologic; Proteasome Inhibitors; Pyrazines | 2012 |
Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, T-Cell, Cutaneous; Middle Aged; NF-kappa B; NF-kappa B p50 Subunit; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sezary Syndrome; Skin Neoplasms; Transcription Factor RelA | 2006 |
Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Glutathione; HIV Reverse Transcriptase; HIV-1; Humans; Kinetics; Lymphoma, T-Cell, Cutaneous; Molecular Structure; NAD(P)H Dehydrogenase (Quinone); Pyrazines; Reverse Transcriptase Inhibitors; Skin Neoplasms; Thiones; Thiophenes; Time Factors; Tumor Cells, Cultured; Virus Replication; Zidovudine | 1993 |